Immune cells from cord blood aim to wipe out hidden colon cancer
NCT ID NCT05040568
First seen Jan 28, 2026 · Last updated May 29, 2026 · Updated 15 times
Summary
This early-phase study tested a combination therapy in 15 people with colon cancer who had completed standard treatment but still had tiny amounts of cancer DNA in their blood (called minimal residual disease). The treatment used specially activated immune cells from donated umbilical cord blood, given together with a targeted drug called cetuximab. The goal was to see if this approach could clear the remaining cancer cells and prevent the disease from coming back.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLON CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.